Working with “living therapies” during COVID-19 has changed access, resource planning and management in CGT trials.


This ICON sponsored webinar program explores the bioethics of clinical trials at Preclinical and Phase 1 stages. An in-depth look at the unique nuances of cell and gene therapy (CGT) trials and how to keep them on track during COVID-19 will follow. The expert panel will conclude with a discussion on strategies for patient advocacy within this changed environment.

Register for the upcoming webinar to learn:

  • What is the ethical protocol of approaching patients for early-stage clinical trials?
  • What are the key differences between CGT clinical trials and traditional models?
  • How has COVID-19 changed accessibility, resource planning and management of CGT trials?
  • How has patient advocacy and support changed in the face of a global pandemic?


Tamie Joeckel

Global Business Lead, Cell and Gene Therapy, ICON

Steven Devine, MD, PhD

Chief Medical Officer, National Marrow Donor Program (NMDP)®/ Be The Match®

Julie Walters

Patient Advocate and Founder, Raremark

Mark Yarborough, PhD

Dean’s Professor of Bioethics, University of California Davis

This webinar is sponsored by ICON in collaboration with the ISCT Market Access & Patient Advocacy (MAPA) Commercialization Subcommittee.